2019 Fellows Courses

Learning Objectives: 

1. Discuss the delays in action of oral P2Y12 inhibitor therapy in stable and acute coronary syndromes, and the available adjunctive methods to ensure adequate dual-antiplatelet inhibition at the time of PCI.
2. Analyze the factors involved in determining the choice and duration of dual-antiplatelet therapy.
3. Describe optimal pharmacotherapy of the peripheral vascular disease patient after revascularization.
4. Identify the patients that will benefit from PCSK9 inhibitors and low-dose rivaroxaban to reduce cardiovascular events.